Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.29 AUD -4.92% Market Closed
Market Cap: 112.9m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PAR stock under the Base Case scenario is 0.28 AUD. Compared to the current market price of 0.29 AUD, Paradigm Biopharmaceuticals Ltd is Overvalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PAR Relative Value
Base Case
0.28 AUD
Overvaluation 3%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

19.9
P/S
P/S
Price to Sales
19.9
vs History
79
vs Industry
28
Median 3Y
27.7
Median 5Y
39.7
Industry
6.5
Forward
37.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-8.9
Industry
22
Forward
-4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-9.4
Industry
18.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-9.4
Industry
23.4
More Details
3.3
P/B
P/B
Price to Book Value
3.3
vs History
88
vs Industry
22
Median 3Y
4.5
Median 5Y
5.6
Industry
2.2
More Details
15.5
EV/S
EV/S
Enterprise Value to Sales
15.5
vs History
77
vs Industry
25
Median 3Y
23.2
Median 5Y
34.7
Industry
7.1
Forward
29.1
More Details
15.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.6
vs History
52
vs Industry
23
Median 3Y
23.4
Median 5Y
15.9
Industry
8.7
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-7.3
Industry
3.3
Forward
-1.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-7.3
Industry
3.1
Forward
-1.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3
Median 5Y
-8.2
Industry
4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3
Median 5Y
-8.2
Industry
2.6
More Details
8.8
EV/IC
EV/IC
Enterprise Value to IC
8.8
vs History
85
vs Industry
17
Median 3Y
29
Median 5Y
49.2
Industry
4.3
More Details

Multiples Across Competitors

PAR Competitors Multiples
Paradigm Biopharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
112.9m AUD 19.9 -7.2 -5.6 -5.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 246 263.5 -167 520.3 -203 423 -201 101.7
US
Abbvie Inc
NYSE:ABBV
309B USD 5.5 72.9 14.6 22.1
US
Amgen Inc
NASDAQ:AMGN
153.5B USD 4.6 37.5 15.4 27.3
US
Gilead Sciences Inc
NASDAQ:GILD
129.1B USD 4.5 269 10.6 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.4B USD 11.3 -232.3 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 998.8 -510 -555.4 -540.6
AU
CSL Ltd
ASX:CSL
112.9B AUD 4.7 25.8 16.1 20.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD 4.3 13.8 8.3 9.2
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59 -63.6 -57.4
NL
argenx SE
XBRU:ARGX
30.5B EUR 15.7 41.2 303.1 -2 232.9
P/S Multiple
Revenue Growth P/S to Growth
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average P/S: 3 204 395.6
19.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
35 246 263.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.5
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
1 998.8
N/A N/A
AU
CSL Ltd
ASX:CSL
4.7
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
7%
0.6
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
NL
argenx SE
XBRU:ARGX
15.7
37%
0.4
P/E Multiple
Earnings Growth PEG
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average P/E: 76.7
Negative Multiple: -7.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 520.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
72.9
87%
0.8
US
Amgen Inc
NASDAQ:AMGN
37.5
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
269
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -232.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -510 N/A N/A
AU
CSL Ltd
ASX:CSL
25.8
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A N/A
NL
argenx SE
XBRU:ARGX
41.2
26%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average EV/EBITDA: 56.2
Negative Multiple: -5.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -203 423 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
14%
1
US
Amgen Inc
NASDAQ:AMGN
15.4
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -555.4 N/A N/A
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.3
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.6 N/A N/A
NL
argenx SE
XBRU:ARGX
303.1
166%
1.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average EV/EBIT: 19.8
Negative Multiple: -5.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 101.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
27.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -540.6 N/A N/A
AU
CSL Ltd
ASX:CSL
20.1
14%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.2
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 232.9 N/A N/A

See Also

Summary
PAR intrinsic value, competitors valuation, and company profile.
DCF Valuation
PAR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PAR stock valuation using valuation multiples.
Wall Street Estimates
PAR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PAR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 246,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.